Analysis Tools
immune system
| N |
• normal lymphocyte development and subset distribution
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• normal lymphocyte development and subset distribution
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fastm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Faslpr homozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fastm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Faslpr homozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 75% of mice die between 10 and 18 months of age
|
|
• loss of B and T cells is at least in part the result of increased apoptosis
|
|
• thymus cell numbers decline from normal at 2 months of age to about 50% and 10% of control at 5 and 7 months of age, respectively
• occasionally complete thymic involution is seen at 7 months of age
|
|
• treatment with a neutralizing Fasl antibody results in accumulation of Thy1+ B220+ CD4- CD8- cells similar to the phenotype of Faslpr homozygous mice
|
|
• gradual decline in B cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes
• treatment with a neutralizing Fasl antibody prevents loss of B cells from the inguinal lymph nodes
|
|
• the fraction of activated/memory T cells in the spleen increases from nearly normal at 2 months of age to about 91% at 7 months of age
|
|
• gradual decline in T cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes
• treatment with a neutralizing Fasl antibody prevents loss of T cells from the inguinal lymph nodes
|
|
• about 50% of peripheral T cell are activated at 5 months of age
• the fraction of activated/memory T cells in the spleen increases from nearly normal at 2 months of age to about 91% at 7 months of age
• these activated T cells express very high levels of FASL at 5 months of age
|
|
• enlarged with disruption of the architecture, loss of white pulp, sclerosis , and hyalinization at 5 months of age
|
|
• gradual decline in total cells, T cells, and B cells
• T cells and B cells are about 160% of control at 2 months, 60% of control at 5 months and 23% (T cells) and 44% (B cells) of control at 7 months
• widespread apoptosis is seen at 16 weeks of age
|
|
• gradual decline in B and T cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes
• loss of B and T cells is at least in part the result of increased apoptosis
• at 5 months of age in 6 of 8 mice inguinal lymph nodes contain fewer than 0.1 million cells and at 7 months in 4 of 4 mice inguinal lymph nodes are almost empty
• treatment with a neutralizing Fasl antibody prevents loss of B and T cells from the inguinal lymph nodes
|
|
• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fastm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Faslpr homozygotes
|
|
• mild to moderate inflammatory cell infiltration
|
|
• mild to moderate inflammatory cell infiltration
|
|
• lung disease begins with infiltration of T and B cells predominantly around the arteries and bronchi around 5 months of age and this is accompanied by high levels of apoptosis
• treatment with a neutralizing Fasl antibody prevents lymphocyte infiltration
|
|
• intense alveolitis with infiltration of lymphocytes, neutrophils, and activated macrophages at 10 months of age
|
|
• at 10 months of age, mice develop a severe wasting syndrome with loss of about 30% of their body weight
|
|
• enlarged with disruption of the architecture, loss of white pulp, sclerosis , and hyalinization at 5 months of age
|
|
• lung disease begins with infiltration of T and B cells predominantly around the arteries and bronchi around 5 months of age and this is accompanied by high levels of apoptosis
• treatment with a neutralizing Fasl antibody prevents lymphocyte infiltration
|
|
• intense alveolitis with infiltration of lymphocytes, neutrophils, and activated macrophages at 10 months of age
|
|
• at 10 months of age, mice develop severe inflammatory pulmonary fibrosis with massive accumulation of elastic fibers and intense alveolitis
|
|
• mild to moderate inflammatory cell infiltration
|
|
• mild to moderate inflammatory cell infiltration
|
|
• loss of B and T cells is at least in part the result of increased apoptosis
|
|
• thymus cell numbers decline from normal at 2 months of age to about 50% and 10% of control at 5 and 7 months of age, respectively
• occasionally complete thymic involution is seen at 7 months of age
|
|
• enlarged with disruption of the architecture, loss of white pulp, sclerosis , and hyalinization at 5 months of age
|
|
• treatment with a neutralizing Fasl antibody results in accumulation of Thy1+ B220+ CD4- CD8- cells similar to the phenotype of Faslpr homozygous mice
|
|
• gradual decline in B cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes
• treatment with a neutralizing Fasl antibody prevents loss of B cells from the inguinal lymph nodes
|
|
• the fraction of activated/memory T cells in the spleen increases from nearly normal at 2 months of age to about 91% at 7 months of age
|
|
• gradual decline in T cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes
• treatment with a neutralizing Fasl antibody prevents loss of T cells from the inguinal lymph nodes
|
|
• about 50% of peripheral T cell are activated at 5 months of age
• the fraction of activated/memory T cells in the spleen increases from nearly normal at 2 months of age to about 91% at 7 months of age
• these activated T cells express very high levels of FASL at 5 months of age
|
|
• widespread apoptosis is seen at 16 weeks of age
• T cells and B cells are about 160% of control at 2 months, 60% of control at 5 months and 23% (T cells) and 44% (B cells) of control at 7 months
• gradual decline in total cells, T cells, and B cells
|
|
• loss of B and T cells is at least in part the result of increased apoptosis
|
|
• thymus cell numbers decline from normal at 2 months of age to about 50% and 10% of control at 5 and 7 months of age, respectively
• occasionally complete thymic involution is seen at 7 months of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 7 months of age, lymph nodes contain fewer than 0.1 million cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• after Poly(I) Poly(C) induction of cre expression mice develop the lymphoproliferative disease seen in Fastm1.1Cgn homozygtes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• similar to mice with recombination only in T cells
|
|
• similar to mice with recombination only in T cells
|
|
• similar to mice with recombination only in T cells
|
|
• similar to mice with recombination only in T cells
|
|
• similar to mice with recombination only in T cells
|
|
• similar to mice with recombination only in T cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 5-fold enlargement
|
|
• 17-fold enlargement in the lymph nodes
• weight of the enlarged lymph nodes is still 200- to 300-fold less than in Fastm1.1Cgn Faslpr trans-heterozygous mice
|
|
• 5-fold enlargement
|
|
• 5-fold enlargement
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• B and T cell distribution in the lymph nodes is normal
• the fraction of B220+ T cells in the lymph nodes and the thymic distribution of CD4/CD8 cells are similar to wild-type
|
|
• mice are almost completely resistant to induction of experimental autoimmune encephalomyelitis (EAE) by injection of MOG p35-55
• almost no oligodendrocyte apoptosis after EAE induction unlike in wild-type mice
• reduction in demyelination and inflammation after induction of EAE is greater than in mutant mice wild-type for Tnfrsf1a
• 24 days after induction of EAE, minimal axonal injury is seen in spinal cords
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• the fraction of B220+ T cells in the lymph nodes and the thymic distribution of CD4/CD8 cells are similar to wild-type
|
|
• reduction in the onset and severity, but not incidence, of experimental autoimmune encephalomyelitis (EAE) induced by injection of MOG p35-55
• demyelination induced by injection of MOG p35-55 is reduced by about 70% compared to wild-type
• perivascular and parenchymal infiltration by T lymphocytes and macrophages is also reduced after induction of EAE
• mild reduction in oligodendrocyte apoptosis after EAE induction
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 4 of 5 mice had 2 fold enlargement
|
|
• 12-fold enlargement in the lymph nodes
• weight of the enlarged lymph nodes is still 200- to 300-fold less than in Fastm1.1Cgn Faslpr trans-heterozygous mice
|
|
• 4 of 5 mice had 2 fold enlargement
|
|
• 4 of 5 mice had 2 fold enlargement
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• reduction in the onset and severity, but not incidence of experimental autoimmune encephalomyelitis (EAE) induced by injection of MOG p35-55
• about a 75% reduction in oligodendrocyte apoptosis after EAE induction compared to wild-type mice
• inflammation after EAE induction is also reduced
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/09/2024 MGI 6.23 |
|
|
|
||